| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 158, Issue 2 756-764, Copyright © 1997 by American Association of Immunologists
ARTICLES |
NI Obiri, P Leland, T Murata, W Debinski and RK Puri
Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Food and Drug Administration, Center for Biologics Evaluation and Research, Bethesda, MD 20892, USA.
We have reported on the expression and characteristics of IL-13R and have demonstrated that IL-13 competes for IL-4 binding while IL-4 did not compete for the IL-13 binding on some cell types. Based on these observations, and the size of IL-13 and IL-4 cross-linked proteins, we concluded that the receptor for IL-13 is complex and shares a subunit with the receptor for IL-4. To explore the complexity of the IL-13R, a wide variety of cell types was examined for IL-13 and IL-4 binding. We report in this work that IL-4 does not always bind well to cells that bind IL-13, but the reverse is also true. We also found that IL-4 can compete more effectively for IL-13 binding than IL-13 itself. Cross- linking studies support these observations and demonstrate that 125I- labeled IL-13 bound exclusively to a single 65- to 70-kDa protein in MA- RCC and U251 cells, while in TF-1 cells it cross-linked to two membrane proteins of 65 to 70 kDa and 140 kDa. Furthermore, by using a chimeric protein composed of IL-13 and Pseudomonas exotoxin A, we observed that IL-4 neutralized the cytotoxicity of the IL-13 toxin on COS-7 cells by blocking a common form of the two cytokine receptors. We propose that the 65- to 70-kDa form of the IL-13R is the predominant common component shared between IL-13 and IL-4R. However, the primary IL-4 binding (p140) protein also participates in the formation of the IL-13R complex in some cell types. In addition, the gamma(c) or another interactive subunit may influence IL-13 binding to its receptor complex. Thus, we propose that there are at least four forms of IL-13R.
This article has been cited by other articles:
|
|
 |
|
  E. W. Lai, B. H. Joshi, L. Martiniova, R. Dogra, T. Fujisawa, P. Leland, R. R. de Krijger, I. A. Lubensky, A. G. Elkahloun, J. C. Morris, et al. Overexpression of Interleukin-13 Receptor-{alpha}2 in Neuroendocrine Malignant Pheochromocytoma: A Novel Target for Receptor Directed Anti-Cancer Therapy J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2952 - 2957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Joshi, P. Leland, A. Calvo, J. E. Green, and R. K. Puri Human Adrenomedullin Up-regulates Interleukin-13 Receptor {alpha}2 Chain in Prostate Cancer In vitro and In vivo: A Novel Approach to Sensitize Prostate Cancer to Anticancer Therapy Cancer Res., November 15, 2008; 68(22): 9311 - 9317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. H. Joshi, R. A. Puri, P. Leland, F. Varricchio, G. Gupta, M. Kocak, R. J. Gilbertson, R. K. Puri, and the U.S. Pediatric Brain Tumor Consortium Identification of interleukin-13 receptor {alpha}2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma Neuro-oncol, January 1, 2008; 10(3): 265 - 274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. C. Webb, Y. Cai, K. I. Matthaei, and P. S. Foster Comparative Roles of IL-4, IL-13, and IL-4R{alpha} in Dendritic Cell Maturation and CD4+ Th2 Cell Function J. Immunol., January 1, 2007; 178(1): 219 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Jakubzick, E S Choi, S L Kunkel, H Evanoff, F J Martinez, R K Puri, K R Flaherty, G B Toews, T V Colby, E A Kazerooni, et al. Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia J. Clin. Pathol., May 1, 2004; 57(5): 477 - 486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kawakami, M. Kawakami, and R. K. Puri Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease Mol. Cancer Ther., February 1, 2004; 3(2): 137 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Webb, K. I. Matthaei, Y. Cai, A. N. J. McKenzie, and P. S. Foster Polymorphisms in IL-4R{alpha} Correlate with Airways Hyperreactivity, Eosinophilia, and Ym Protein Expression in Allergic IL-13-/- Mice J. Immunol., January 15, 2004; 172(2): 1092 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jakubzick, E. S. Choi, B. H. Joshi, M. P. Keane, S. L. Kunkel, R. K. Puri, and C. M. Hogaboam Therapeutic Attenuation of Pulmonary Fibrosis Via Targeting of IL-4- and IL-13-Responsive Cells J. Immunol., September 1, 2003; 171(5): 2684 - 2693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kawakami, M. Kawakami, S. R. Husain, and R. K. Puri Effect of Interleukin (IL)-4 Cytotoxin on Breast Tumor Growth after in Vivo Gene Transfer of IL-4 Receptor {alpha} Chain Clin. Cancer Res., May 1, 2003; 9(5): 1826 - 1836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kawakami, K. Kawakami, and R. K. Puri Intratumor Administration of Interleukin 13 Receptor-targeted Cytotoxin Induces Apoptotic Cell Death in Human Malignant Glioma Tumor Xenografts Mol. Cancer Ther., October 1, 2002; 1(12): 999 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Roy, A. Bhattacharjee, B. Xu, D. Ford, A. L. Maizel, and M. K. Cathcart IL-13 signal transduction in human monocytes: phosphorylation of receptor components, association with Jaks, and phosphorylation/activation of Stats J. Leukoc. Biol., September 1, 2002; 72(3): 580 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Joshi, K. Kawakami, P. Leland, and R. K. Puri Heterogeneity in Interleukin-13 Receptor Expression and Subunit Structure in Squamous Cell Carcinoma of Head and Neck: Differential Sensitivity to Chimeric Fusion Proteins Comprised of Interleukin-13 and a Mutated Form of Pseudomonas Exotoxin Clin. Cancer Res., June 1, 2002; 8(6): 1948 - 1956. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Li, W. A. Hall, N. Jin, D. A. Todhunter, A. Panoskaltsis-Mortari, and D. A. Vallera Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice Protein Eng. Des. Sel., May 1, 2002; 15(5): 419 - 427. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Vallera, C. Li, N. Jin, A. Panoskaltsis-Mortari, and W. A. Hall Targeting Urokinase-Type Plasminogen Activator Receptor on Human Glioblastoma Tumors With Diphtheria Toxin Fusion Protein DTAT J Natl Cancer Inst, April 17, 2002; 94(8): 597 - 606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Fukuda, Y. Fujitsu, N. Kumagai, and T. Nishida Characterization of the Interleukin-4 Receptor Complex in Human Corneal Fibroblasts Invest. Ophthalmol. Vis. Sci., January 1, 2002; 43(1): 183 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kawakami, M. Kawakami, P. J. Snoy, S. R. Husain, and R. K. Puri In Vivo Overexpression of IL-13 Receptor {alpha}2 Chain Inhibits Tumorigenicity of Human Breast and Pancreatic Tumors in Immunodeficient Mice J. Exp. Med., December 17, 2001; 194(12): 1743 - 1754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Madison and M. F. Ethier Interleukin-4 Rapidly Inhibits Calcium Transients in Response to Carbachol in Bovine Airway Smooth Muscle Cells Am. J. Respir. Cell Mol. Biol., August 1, 2001; 25(2): 239 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kawakami, M. Kawakami, B. H. Joshi, and R. K. Puri Interleukin-13 Receptor-targeted Cancer Therapy in an Immunodeficient Animal Model of Human Head and Neck Cancer Cancer Res., August 1, 2001; 61(16): 6194 - 6200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Debinski, B. H. Joshi, G. E. Plautz, and R. K. Puri Correspondence re: B. H. Joshi et al., Interleukin-13 Receptor {alpha} Chain: A Novel Tumor-associated Transmembrane Protein in Primary Explants of Human Malignant Gliomas. Cancer Res., 60: 1168-1172, 2000. Cancer Res., July 1, 2001; 61(14): 5660 - 5660. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kawakami, J. Taguchi, T. Murata, and R. K. Puri The interleukin-13 receptor {alpha}2 chain: an essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway Blood, May 1, 2001; 97(9): 2673 - 2679. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Monson, T. J. Fenske, S. Wei, A. J. Okragly, J. L.O. de Jong, M. Haak-Frendscho, J. O’Shea, J. Djeu, and P. M. Sondel A p74 common gamma receptor chain isoform facilitates IL-2 and IL-15 responses by the myelomonocytic cell line Tf-1{beta}2 J. Leukoc. Biol., March 1, 2001; 69(3): 419 - 425. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y. Oshima, B. H. Joshi, and R. K. Puri Conversion of Interleukin-13 into a High Affinity Agonist by a Single Amino Acid Substitution J. Biol. Chem., May 5, 2000; 275(19): 14375 - 14380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Joshi, G. E. Plautz, and R. K. Puri Interleukin-13 Receptor {{alpha}} Chain: A Novel Tumor-associated Transmembrane Protein in Primary Explants of Human Malignant Gliomas Cancer Res., March 1, 2000; 60(5): 1168 - 1172. [Abstract] [Full Text]
|
|
|
|
|
|
J. P. Thompson and W. Debinski Mutants of Interleukin 13 with Altered Reactivity toward Interleukin 13 Receptors J. Biol. Chem., October 15, 1999; 274(42): 29944 - 29950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ford, C. Sheehan, C. Girasole, R. Priester, N. Kouttab, J. Tigges, T. C. King, A. Luciani, J. W. Morgan, and A. L. Maizel The Human B Cell Response to IL-13 Is Dependent on Cellular Phenotype as Well as Mode of Activation J. Immunol., September 15, 1999; 163(6): 3185 - 3193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Wright, G. Kolios, J. Westwick, and S. G. Ward Cytokine-induced Apoptosis in Epithelial HT-29 Cells Is Independent of Nitric Oxide Formation. EVIDENCE FOR AN INTERLEUKIN-13-DRIVEN PHOSPHATIDYLINOSITOL 3-KINASE-DEPENDENT SURVIVAL MECHANISM J. Biol. Chem., June 11, 1999; 274(24): 17193 - 17201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Debinski, D. M. Gibo, S. W. Hulet, J. R. Connor, and G. Y. Gillespie Receptor for Interleukin 13 Is a Marker and Therapeutic Target for Human High-Grade Gliomas Clin. Cancer Res., May 1, 1999; 5(5): 985 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. K. Puri Toxicologic Pathology of Cytokines, Cytokine Receptors, and Other Recombinant Human Proteins: Development of a Recombinant Interleukin-4-Pseudomonas Exotoxin for Therapy of Glioblastoma Toxicol Pathol, January 1, 1999; 27(1): 53 - 57. [Abstract] [PDF]
|
|
|
|
|
|
Y. H. Lai and T. R. Mosmann Mouse IL-13 Enhances Antibody Production In Vivo and Acts Directly on B Cells In Vitro to Increase Survival and Hence Antibody Production J. Immunol., January 1, 1999; 162(1): 78 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, F. E. R. Simons, and K. T. HayGlass Environmental Antigen-Induced IL-13 Responses Are Elevated Among Subjects with Allergic Rhinitis, Are Independent of IL-4, and Are Inhibited by Endogenous IFN-{gamma} Synthesis J. Immunol., December 15, 1998; 161(12): 7007 - 7014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Manna and B. B. Aggarwal Interleukin-4 Down-regulates Both Forms of Tumor Necrosis Factor Receptor and Receptor-mediated Apoptosis, NF-kappa B, AP-1, and c-Jun N-Terminal Kinase. COMPARISON WITH INTERLEUKIN-13 J. Biol. Chem., December 11, 1998; 273(50): 33333 - 33341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Roy and M. K. Cathcart Induction of 15-Lipoxygenase Expression by IL-13 Requires Tyrosine Phosphorylation of Jak2 and Tyk2 in Human Monocytes J. Biol. Chem., November 27, 1998; 273(48): 32023 - 32029. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Whitty, N. Raskin, D. L. Olson, C. W. Borysenko, C. M. Ambrose, C. D. Benjamin, and L. C. Burkly Interaction affinity between cytokine receptor components on the cell surface PNAS, October 27, 1998; 95(22): 13165 - 13170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Murata, J. Taguchi, and R. K. Puri Interleukin-13 Receptor alpha ' But Not alpha Chain: A Functional Component of Interleukin-4 Receptors Blood, May 15, 1998; 91(10): 3884 - 3891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ogata, D. Ford, N. Kouttab, T. C. King, N. Vita, A. Minty, J. Stoeckler, D. Morgan, C. Girasole, J. W. Morgan, et al. Regulation of Interleukin-13 Receptor Constituents on Mature Human B Lymphocytes J. Biol. Chem., April 17, 1998; 273(16): 9864 - 9871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Bonder, H. L. Dickensheets, J. J. Finlay-Jones, R. P. Donnelly, and P. H. Hart Involvement of the IL-2 Receptor {gamma}-Chain ({gamma}c) in the Control by IL-4 of Human Monocyte and Macrophage Proinflammatory Mediator Production J. Immunol., April 15, 1998; 160(8): 4048 - 4056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. I. Obiri, T. Murata, W. Debinski, and R. K. Puri Modulation of Interleukin (IL)-13 Binding and Signaling by the gamma c Chain of the IL-2 Receptor J. Biol. Chem., August 8, 1997; 272(32): 20251 - 20258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Oshima and R. K. Puri Characterization of a Powerful High Affinity Antagonist That Inhibits Biological Activities of Human Interleukin-13 J. Biol. Chem., April 27, 2001; 276(18): 15185 - 15191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kawakami, F. Takeshita, and R. K. Puri Identification of Distinct Roles for a Dileucine and a Tyrosine Internalization Motif in the Interleukin (IL)-13 Binding Component IL-13 Receptor alpha 2 Chain J. Biol. Chem., June 29, 2001; 276(27): 25114 - 25120. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
